These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32118513)

  • 21. 2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network.
    Bettinger JA; De Serres G; Valiquette L; Vanderkooi OG; Kellner JD; Coleman BL; Top KA; Isenor JE; McCarthy AE;
    Euro Surveill; 2020 Jun; 25(22):. PubMed ID: 32524947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season.
    Gandhi-Banga S; Chabanon AL; Eymin C; Caroe T; Butler K; Moureau A
    Hum Vaccin Immunother; 2019; 15(9):2154-2158. PubMed ID: 30897026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women.
    Munoz FM; Jackson LA; Swamy GK; Edwards KM; Frey SE; Stephens I; Ault K; Winokur P; Petrie CR; Wolff M; Patel SM; Keitel WA
    Vaccine; 2018 Dec; 36(52):8054-8061. PubMed ID: 30416018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: the importance of routine active safety surveillance.
    Petousis-Harris H; Poole T; Turner N; Reynolds G
    Vaccine; 2012 Jul; 30(33):4945-52. PubMed ID: 22664224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three seasons of enhanced safety surveillance of a cell culture-based quadrivalent influenza vaccine.
    Domnich A; Amicizia D; Lai PL; Ogliastro M; Piedrahita-Tovar M; Orsi A; Icardi G; Panatto D
    Hum Vaccin Immunother; 2023 Aug; 19(2):2261689. PubMed ID: 37787067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful methodology for large-scale surveillance of severe events following influenza vaccination in Canada, 2011 and 2012.
    Bettinger JA; Rouleau I; Gariepy MC; Bowie WR; Valiquette L; Vanderkooi OG; Kellner JD; Coleman BL; McNeil SA; McCarthy A; De Serres G;
    Euro Surveill; 2015 Jul; 20(29):21189. PubMed ID: 26227369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Active surveillance for safety monitoring of seasonal influenza vaccines in Italy, 2015/2016 season.
    Spila Alegiani S; Alfonsi V; Appelgren EC; Ferrara L; Gallo T; Alicino C; Pascucci MG; Aquilani S; Spadea A; Tafuri S; Rizzo C
    BMC Public Health; 2018 Dec; 18(1):1401. PubMed ID: 30577729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: A self-controlled case-series.
    Dos Santos G; Haguinet F; Cohet C; Webb D; Logie J; Ferreira GL; Rosillon D; Shinde V
    Vaccine; 2016 Jun; 34(31):3598-606. PubMed ID: 27216760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 μg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season.
    Chabanon AL; Bricout H; Ballandras C; Souverain A; Caroe TD; Butler KM
    Hum Vaccin Immunother; 2018 Feb; 14(2):378-385. PubMed ID: 29148911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluarix quadrivalent vaccine for influenza.
    Graaf Hd; Faust SN
    Expert Rev Vaccines; 2015; 14(8):1055-63. PubMed ID: 26098443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England.
    McNaughton R; Lynn E; Osborne V; Coughtrie A; Layton D; Shakir S
    Drug Saf; 2016 Apr; 39(4):323-33. PubMed ID: 26798051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Technical guidelines for seasonal influenza vaccination in China (2020-2021)].
    National Immunization Advisory Committee Technical Working Group
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Oct; 54(10):1035-1059. PubMed ID: 33131228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical data on Fluarix: an inactivated split seasonal influenza vaccine.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Aug; 7(6):713-9. PubMed ID: 18665769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-vaccination healthcare attendance rate as a proxy measure for syndromic surveillance of adverse events following immunisation.
    Mesfin YM; Cheng AC; Enticott J; Lawrie J; Buttery J
    Aust N Z J Public Health; 2021 Apr; 45(2):101-107. PubMed ID: 33617131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.
    Omeñaca F; Vázquez L; Garcia-Corbeira P; Mesaros N; Hanssens L; Dolhain J; Gómez IP; Liese J; Knuf M
    Vaccine; 2018 Feb; 36(7):986-996. PubMed ID: 29336924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surveillance for Guillain-Barré syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare beneficiaries.
    Arya DP; Said MA; Izurieta HS; Perez-Vilar S; Zinderman C; Wernecke M; Alexander M; White T; Su IH; Lufkin B; MaCurdy T; Kelman J; Forshee R
    Vaccine; 2019 Oct; 37(43):6543-6549. PubMed ID: 31515146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
    Squarcione S; Sgricia S; Biasio LR; Perinetti E
    Vaccine; 2003 Mar; 21(11-12):1268-74. PubMed ID: 12559808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia.
    Pillsbury AJ; Glover C; Jacoby P; Quinn HE; Fathima P; Cashman P; Leeb A; Blyth CC; Gold MS; Snelling T; Macartney KK
    BMJ Open; 2018 Oct; 8(10):e023263. PubMed ID: 30341132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Technical guidelines for seasonal influenza vaccination in China (2020-2021)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Oct; 41(10):1555-1576. PubMed ID: 33297613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Study on surveillance data of adverse events following immunization of seasonal influenza vaccine in China during 2015-2018 influenza season].
    Wu WD; Li KL; Xu DS; Ye JK; Xiao QY; Wang HQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):987-992. PubMed ID: 31607043
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.